Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

BridgeBio Scores Another Win with Rare Disease Drug Encaleret

BridgeBio Scores Another Win with Rare Disease Drug Encaleret

BridgeBio Pharma has announced positive results from a late-stage clinical trial for encaleret, its experimental treatment for autosomal dominant hypocalcemia Type 1 (ADH1), marking another significant advancement in the company's rare disease research portfolio.

NoahAI News10/29/2025
CVS Health Reports Strong Q3 Results, Raises Full-Year Guidance Amid Strategic Shifts

CVS Health Reports Strong Q3 Results, Raises Full-Year Guidance Amid Strategic Shifts

CVS Health Corporation, a leading healthcare company, reported robust third-quarter results for 2025, surpassing Wall Street expectations and prompting an increase in its full-year earnings forecast. The company's performance reflects significant improvements across its diversified business segments, despite facing challenges in its healthcare delivery unit.

NoahAI News10/29/2025
GSK Abandons CD226 Cancer Therapies, Shifts Focus in Pharmaceutical Pipeline

GSK Abandons CD226 Cancer Therapies, Shifts Focus in Pharmaceutical Pipeline

GSK, a leading pharmaceutical company, has announced significant changes to its drug development pipeline, marking a strategic shift in its oncology and infectious disease programs. The company's third-quarter earnings report revealed the discontinuation of several key projects, most notably its ambitious CD226 axis cancer therapies.

NoahAI News10/29/2025
M&A Activity Heats Up in Small- to Mid-Cap Pharmaceutical Sector

M&A Activity Heats Up in Small- to Mid-Cap Pharmaceutical Sector

In a landscape traditionally dominated by Big Pharma megadeals, a new trend is emerging in the pharmaceutical industry: small- to mid-cap companies are increasingly positioned as prime candidates for mergers and acquisitions. This shift reflects a growing appetite for targeted acquisitions that can bolster pipelines and drive meaningful growth without the complexities of integrating industry giants.

NoahAI News10/29/2025
Nvidia Expands Footprint in Life Sciences with High-Profile Partnerships

Nvidia Expands Footprint in Life Sciences with High-Profile Partnerships

Nvidia, the technology giant known for its graphics processing units and AI capabilities, is making significant strides in the life sciences sector through a series of strategic partnerships. Recent deals with Johnson & Johnson's medical technology unit (J&J MedTech), Verily, and Eli Lilly underscore Nvidia's commitment to revolutionizing healthcare and pharmaceutical research using advanced AI and simulation technologies.

NoahAI News10/29/2025
J&J Partners with Nvidia to Integrate AI into Urology Robotics Platform

J&J Partners with Nvidia to Integrate AI into Urology Robotics Platform

Johnson & Johnson MedTech has announced a groundbreaking partnership with Nvidia to incorporate artificial intelligence into its Monarch robotic platform for urological procedures. This collaboration marks a significant step forward in the integration of AI technology in medical robotics, particularly for kidney stone treatments.

NoahAI News10/29/2025
Novartis CEO Critiques Trump's Drug Pricing Deals as Industry Braces for Change

Novartis CEO Critiques Trump's Drug Pricing Deals as Industry Braces for Change

Novartis CEO Vas Narasimhan has expressed skepticism about President Donald Trump's recent measures to lower drug prices, stating that they fail to address the root causes of high pharmaceutical costs in the United States. This criticism comes as the industry faces increasing pressure to reduce prices and improve affordability for patients.

NoahAI News10/29/2025
Pharmaceutical Industry Faces Wave of Layoffs Amid Strategic Restructuring

Pharmaceutical Industry Faces Wave of Layoffs Amid Strategic Restructuring

The pharmaceutical industry is experiencing a significant upheaval as numerous companies implement workforce reductions and strategic restructuring initiatives. These moves come as firms aim to streamline operations, extend cash runways, and reallocate resources to high-priority programs in a challenging economic environment.

NoahAI News10/29/2025
GSK Expands COPD Portfolio with $85 Million Empirico Deal

GSK Expands COPD Portfolio with $85 Million Empirico Deal

In a significant move to bolster its chronic obstructive pulmonary disease (COPD) pipeline, GlaxoSmithKline (GSK) has announced a partnership with privately held biotech firm Empirico. The deal, valued at up to $745 million, centers around EMP-012, an experimental RNA-based therapy that shows promise in treating a broad spectrum of COPD patients.

NoahAI News10/29/2025
BioMarin Shifts Strategy: Abandons Roctavian, Faces Voxzogo Competition, and Adjusts Revenue Targets

BioMarin Shifts Strategy: Abandons Roctavian, Faces Voxzogo Competition, and Adjusts Revenue Targets

BioMarin Pharmaceutical Inc. has announced significant changes to its business strategy, including the divestment of its hemophilia A gene therapy Roctavian and a revision of its long-term revenue projections. The company's decision comes amid growing competitive pressures and evolving market dynamics in the rare disease space.

NoahAI News10/29/2025
Biogen's Dapirolizumab Pegol Shows Promise in Lupus Treatment, Poised to Compete with Industry Giants

Biogen's Dapirolizumab Pegol Shows Promise in Lupus Treatment, Poised to Compete with Industry Giants

Biogen and UCB's collaborative effort in developing dapirolizumab pegol, a CD40L inhibitor, has yielded impressive results in the treatment of systemic lupus erythematosus (SLE), potentially positioning the drug as a formidable competitor in a market currently dominated by AstraZeneca and GSK.

NoahAI News10/29/2025
Merck's Welireg Scores Big in Kidney Cancer Trials, Bolstering Post-Keytruda Strategy

Merck's Welireg Scores Big in Kidney Cancer Trials, Bolstering Post-Keytruda Strategy

Merck & Co. has announced significant breakthroughs in two Phase 3 trials for its kidney cancer drug Welireg, potentially expanding its use and solidifying the company's position in oncology as it prepares for life after Keytruda's patent expiration.

NoahAI News10/29/2025
«1...151617...67»